Ubs Asset Management Americas Inc Vaxart, Inc. Transaction History

Ubs Asset Management Americas Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.09 - $4.5 $190,202 - $409,527	91,006 Added 82.62%	201,150 $438,000
Q2 2022 Aug 12, 2022	SELL	$2.7 - $5.28 $18,049 - $35,296	-6,685 Reduced 5.72%	110,144 $385,000
Q4 2021 Feb 14, 2022	BUY	$5.77 - $7.96 $38,543 - $53,172	6,680 Added 6.06%	116,829 $732,000
Q2 2021 Aug 16, 2021	BUY	$5.06 - $10.78 $20,477 - $43,626	4,047 Added 3.81%	110,149 $825,000
Q1 2021 May 14, 2021	BUY	$5.64 - $23.33 $18,623 - $77,035	3,302 Added 3.21%	106,102 $641,000
Q4 2020 Mar 01, 2021	BUY	$3.5 - $7.98 $359,800 - $820,344	102,800 New	102,800 $586,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.